NK Cell-AML is under clinical development by HK inno.N and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NK Cell-AML’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NK Cell-AML overview
Gene modified cell therapy is under development for the treatment of acute myeloid leukemia (AML). The drug candidate comprises of genetically engineered NK cells.
HK inno.N overview
HK inno.N, formerly CJ HealthCare, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients, OTC drugs, and pharmaceutical medicines. Its finished product portfolio includes EPOKINE for the treatment of renal anemia, LEUKOKINE to treat neutropenia, CALMTOP for the treatment of colorectal cancer, MOVELOXIN, and CINEZOLID, OMAPONE a parenteral nutrition product, and PEMTA an infusion solution. The company provides OTC drugs such as CJ condition, hongsamjin gold, hutgaesoo, mach max, roboca poli, sankle eye drops and solar vita. The company has production facilities in Icheon, Osong and Daeso; Korea. HK inno.N is headquartered in Seoul, South Korea.
For a complete picture of NK Cell-AML’s drug-specific PTSR and LoA scores, buy the report here.